Background: Nucleosomes are cell death products that are elevated in serum of patients with diseases that are associated with massive cell destruction. We investigated the kinetics of circulating nucleosomes after cerebral stroke and their correlation with the clinical status. Methods: In total, we analyzed nucleosomes by ELISA in sera of 63 patients with early stroke daily during the first week after onset. For correlation with the clinical pathology, patients were grouped into those with medium to slight functional impairment (Barthel Index BI ≧50) and those with severe functional impairment (BI <50). Results: Patients with BI ≧50 showed a continuous increase in nucleosomes until day 5 (median: 523 arbitrary units, AU) followed by a slow decline. In contrast, patients with BI <50 showed a steeper initial increase reaching a maximum already on day 3 (869 AU). Both, days after stroke (p < 0.001) and BI (p < 0.001), had a significant influence on nucleosome concentrations, respectively. Consistently, patients with BI <50 had a significantly larger area under the curve (AUC/day) of nucleosome values during the first week after stroke (800 AU) than patients with BI ≧50 (497 AU; p = 0.031). Concerning the infarction volume, nucleosomes showed significant correlations for the concentrations on day 3 (r = 0.43; p = 0.001) and for the area under the curve (r = 0.34; p = 0.016). Conclusion: Even if nucleosomes are nonspecific cell death markers, their release into serum after cerebral stroke correlates with the gross functional status as well as with the infarction volume and can be considered as biochemical correlative to the severity of stroke.

Keywords:
Nucleosomes, DNA, Apoptosis, Cerebral ischemia, Stroke
1.
Dirnagl U, Iadecola C, Moskowitz MA: Pathobiology of ischemic stroke: an integrated view. Trends Neurosci 1999;22:391–397.
2.
Katsura K, Kristian T, Siesjo BK: Energy metabolism, ion homeostasis, and cell damage in the brain. Biochem Soc Trans 1994;22:991–996.
3.
Siesje BK, Kristian T, Katsura K; in Ginsberg MD, Bogousslavsky J (eds): Cerebrovascular Disease. Oxford, Blackwell Science, 1998, pp 1–13.
4.
Holdenrieder S, Stieber P, Bodenmueller H, Busch M, von Pawel J, Schalhorn A, Nagel D, Seidel D: Circulating nucleosomes in serum. Ann NY Acad Sci 2001;945:93–102.
5.
Lichtenstein AV, Melkonyan HS, Tomei LD, Umansky SR: Circulating nucleic acids and apoptosis. Ann NY Acad Sci 2001;945:239–249.
6.
Holdenrieder S, Stieber P, Bodenmueller H, Busch M, Fertig G, Furst H, Schalhorn A, Schmeller N, Untch M, Seidel D: Nucleosomes in serum of patients with benign and malignant diseases. Int. J Cancer 2001;95:114–120.
7.
Holdenrieder S, Stieber P, Bodenmueller H, Fertig G, Furst H, Schmeller N, Untch M, Seidel D: Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 2001;39:596–605.
8.
Lo YMD, Tein MSC, Pang CCP, Yeung Ck, Tong KL, Hjelm NM: Presence of donor-specific DNA in plasma of kidney and liver transplant recipients. Lancet 1998;351:1329–1330.
9.
Lo YMD, Rainer TH, Chan LYS, Hjelm NM, Cocks RA: Plasma DNA as a prognostic marker in trauma patients. Clin Chem 2000;46:319–323.
10.
Rainer TH, Wong LKS, Lam W, Yuen E, Lam NYL, Metrewel C, Lo YMD: Prognostic use of circulating plasma nucleic acid concentrations in patients with acute stroke. Clin Chem 2003;49:562–569.
11.
Lo YMD, Tein MSC, Lau TK, Haines CJ, Leung TN, Poon PM, Wainscoat JS, Johnson PJ, Chang AM, Hjelm NM: Quantitative analysis of fetal DNA in maternal plasma and serum. Ann J Hum Genet 1998;62:769–775.
12.
Mahoney FI, Barthel D: Functional evaluation: The Barthel Index. Md State Med J 1965;14:56–61.
13.
van Everdingen KJ, van der Grond J, Kapelle LJ, Ramos LM, Mali WP: Diffusion-weighted magnetic resonance imaging in acute stroke. Stroke 1998;29:1783–1790.
14.
İnal-Cevik I, Kilinc M, Can A, Gürsoy-Özdemir Y, Dalkara T: Apoptotic and necrotic death mechanisms are concomitantly activated in the same cell after cerebral ischemia. Stroke 2004;35:2189–2194.
15.
Boysen G, Christensen H: Early stroke: a dynamic process. Stroke 2001;32:2423–2425.
16.
Adams HP Jr, Olinger CP, Maler JR, Biller J, Brott TG, Barsan WC, Banwart K: Comparison of admission serum glucose concentration with neurological outcome in acute infarction: a study in patients given naloxone. Stroke 1998;19:455–458.
17.
Muir KW, Weir CJ, Alwan W, Squire IB, Lees KR: C-reactive-protein and outcome after ischemic stroke. Stroke 1999;30:981–985.
18.
Di Napoli M, Papa F, Bocola V: Prognostic influence of increased C-reactive-protein and fibrinogen levels in ischemic stroke. Stroke 2001;32:133–138.
19.
Missler U, Wiesmann M, Friedrich C, Kaps M: S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarction volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956–1960.
20.
Wunderlich MT, Ebert AD, Kratz T, Goertler M, Jost S, Herrmann M: Early neurobehavioral outcome after stroke is related to release of neurobiochemical markers of brain damage. Stroke 1999;30:1190–1195.
21.
Chan KC, Zhang J, Chan AT, Lei KI, Leung SF, Chan LY, Chow KC, Lo YM: Molecular characterization of circulating EBV-DNA in the plasma of nasopharyngeal carcinoma and lymphoma patients. Cancer Res 2003;63:2028–2032.
22.
Rumore PM, Steinman CR: Endogenous circulating DNA in systemic lupus erythematosus. Occurrence as multimeric complexes bound to histone. J Clin Invest 1990;86:69–74.
23.
Leist M, Nicotera P: The shape of cell death. Biochem Biophys Res Commun 1997;236:1–9.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.